A new era of competition and innovation in metabolic and obesity care Increased focus on oral formulations and patient-centric drug design Regulatory, manufacturing, and market access strategies will become even more critical Obesity is a global health challenge, and innovations like this show how science, regulation, and patient needs can align to create real impact
AHK-Cu, while promising, is still an emerging peptide with ongoing research to fully elucidate its potential
It does not confirm terminal groups, acetate content, net peptide quantity, aggregation, residual solvents or finished-product stability
This gap highlights a key unmet need identified by the present review
It is a sign of defective catabolism of amino acids or ammonia to urea